The Efficacy and Safety of Sofosbuvir Containing Regimen in the Treatment of Hcv Infection in Patients with Haemoglobinopathy

The Efficacy and Safety of Sofosbuvir Containing Regimen in the Treatment of Hcv Infection in Patients with Haemoglobinopathy

Saved in:

Bibliographic Details
Main Author:	Nawfal R Hussein
Format:	Article
Language:	English
Published:	PAGEPress Publications 2017-01-01
Series:	Mediterranean Journal of Hematology and Infectious Diseases
Subjects:	HCV, Thalassaemia, sickle cell, sofosbuvir, DAA
Online Access:	http://www.mjhid.org/index.php/mjhid/article/view/2752
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Prediction of sofosbuvir response using interleukin-6 serum level and single nucleotide polymorphism of interferon lambda- 4
by: Amal E Saafan, et al.
Published: (2020-01-01)

THE USE OF HPLC AS A TOOL FOR NEONATAL CORD BLOOD SCREENING OF HAEMOGLOBINOPATHY - A VALIDATION STUDY
by: A. Al-Madhani, et al.
Published: (2019-01-01)

Impact of Sofosbuvir/Daclatasvir treatment on glycemic control and lipid profile in diabetic patients with chronic hepatitis C
by: Tamer Fouad, et al.
Published: (2025-07-01)

Long-Term Hepatic and Extrahepatic Outcomes of Chronic Hepatitis C Patients After Sofosbuvir-Based Treatment (LONGHEAD Study)
by: Chung-Feng Huang, et al.
Published: (2025-04-01)

Efficacy and safety of directly acting antiviral drugs in HCV patients with HIV in liver transplantation: A meta-analysis
by: Tian Zeng, et al.
Published: (2023-01-01)

Cardiac toxicity associated with HCV direct antiviral agents
by: Claudio Ucciferri, et al.
Published: (2018-10-01)

Antivirals against HCV infection: the story thus far
by: Ahmad Adebayo Irekeola, et al.
Published: (2022-02-01)

Worsening of Controlled Attenuation Parameter and Metabolic Profile After HCV Cure in People with HIV as a Sign of Steatosis
by: Alessia Siribelli, et al.
Published: (2025-06-01)

Real-World Treatment Efficacy and Safety Profile of Sofosbuvir- and Velpatasvir-Based HCV Treatment in South Korea: Multicenter Prospective Study
by: Jae Hyun Yoon, et al.
Published: (2025-07-01)

Impact of HCV elimination on metabolism markers in people living with HIV
by: Andrés Deza de la Casa, et al.
Published: (2025-05-01)

Elimination of HCV replication machinery early after antiviral treatment with DAA monitored by multimodal microscopy
by: Castro Victoria, et al.
Published: (2024-01-01)

Diagnostic approach to elucidate the efficacy and side effects of direct-acting antivirals in HCV infected patients
by: Sonia Younas, et al.
Published: (2021-10-01)

Performance of Elecsys<sup>®</sup> HCV Duo Immunoassay for Diagnosis and Assessment of Treatment Response in HCV Patients with or without HIV Infection
by: Prooksa Ananchuensook, et al.
Published: (2024-09-01)

Analysis of Haemoglobin Profile in Haemoglobinopathies by High Performance Liquid Chromatography and Capillary Zone Electrophoresis Methods: A Cross-sectional Study
by: Pallavi Kommoju, et al.
Published: (2025-04-01)

Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis
by: Shahd Hamran, et al.
Published: (2025-04-01)

Sustained virological response in HCV patients receiving antiviral treatment at a teaching centre of northern India
by: Astha, et al.
Published: (2025-03-01)

Effects of antiviral therapy on reducing the risk of metabolic syndrome in patients with chronic hepatitis C
by: A. F. Novikova, et al.
Published: (2023-07-01)

SARS-CoV-2 and HCV infection and antiviral treatment monitored by multimodal imaging
by: Perez-Berna Ana Joaquina, et al.
Published: (2024-01-01)

Efficacy of Sofosbuvir and Ribavirin in Children Presenting with Hepatitis C at Tertiary Care Hospital, Faisalabad
by: Nagina Shahzadi, et al.
Published: (2023-04-01)

Effectiveness of glecaprevir/pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir/emtricitabine/tenofovir alafenamide
by: Aleksandra Berkan-Kawińska, et al.
Published: (2024-07-01)

A case report of sofosbuvir induced drug eruption and literature review
by: Anyue Xia, et al.
Published: (2025-01-01)

HCC occurrence after DAA treatments: molecular tools to assess the post-treatment risk and surveillance
by: Devis Pascut, et al.
Published: (2020-06-01)

The impact of sofosbuvir/ledipasvir on chronic hepatitis C-infected paediatric patients: a Middle East single-centre experience
by: Mohammad Fadhil Ibraheem, et al.
Published: (2023-11-01)

Peripheral immune signatures associated with the risk of hepatocarcinogenesis in cirrhotic Egyptian HCV patients before and after treatment with direct-acting antivirals
by: Reem El-Shenawy, et al.
Published: (2024-11-01)

Evaluation of Patients' Recovery from Hepatitis C Following Antiviral Treatment with Daclatasvir and Sofosbuvir in AL-Baha Region
by: Fahad Alghamdi, et al.
Published: (2024-06-01)

DEVELOPMENT AND VALIDATION OF A NEW RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION AND QUANTIFICATION OF SOFOSBUVIR AND DACLATASVIR
by: Syed Hassan Murtaza, et al.
Published: (2024-03-01)

Effectiveness and safety of sofosbuvir/velpatasvir in chronic hepatitis C virus infection of Bangladeshi children
by: Salahuddin Mahmud, et al.
Published: (2025-06-01)

Association of multiple mutations in NS5A and NS5B genes and resistance to direct-acting antivirals in chronically infected Egyptian patients with Hepatitis C virus Genotype 4a
by: Gehad M. Mohamed, et al.
Published: (2024-02-01)

Impact of hepatitis C virus genotype on the efficacy of the direct-acting antivirals in chronic kidney disease patients in West Bengal, India
by: Sagnik Bakshi, et al.
Published: (2025-05-01)

HCV-related chronic kidney disease in the era of new direct-acting antivirals regimens
by: Jakub Janczura, et al.
Published: (2025-08-01)

Changes in liver stiffness and steatosis in children after successful treatment with sofosbuvir/velpatasvir: Results of the PANDAA-PED study
by: Maria Pokorska-Śpiewak, et al.
Published: (2024-12-01)

The best anti-HCV S/Co values for reflecting HCV infection in a university hospital in the eastern part of Turkey
by: Bülent Dabanlıoğlu, et al.
Published: (2024-01-01)

Impact of Sofosbuvir Plus Daclatasvir Therapy on the Frequency of CD200R<sup>+</sup> Dendritic Cells in Chronic Hepatitis C Virus Infection
by: Helal F. Hetta, et al.
Published: (2024-12-01)

A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs)
by: Lorenza Di Marco, et al.
Published: (2025-01-01)

Threshold value of the anti-HCV test in the diagnosis of HCV infection
by: Özlem Kirişci, et al.
Published: (2019-10-01)

Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from Türkiye
by: Umut Devrim Binay, et al.
Published: (2025-06-01)

Efficacy and safety of sofosbuvir plus daclatasvir in hemodialysis patients with genotype 1b or 2a hepatitis C virus infection: a single-arm, prospective real-world study
by: Kaili Wang, et al.
Published: (2025-07-01)

Real world experience with the all-oral interferon free regimen for the treatment of chronic hepatitis c virus infection in the Lebanese population
by: Jowana Saba, et al.
Published: (2018-02-01)

Effectiveness of sofosbuvir-based treatments for patients with hepatitis C virus genotype 6 infection: a real-world study from East China
by: Fan-Rong Jiang, et al.
Published: (2024-11-01)

Use of Hepatitis C Viremic Donors to Expand the Pediatric Donor Pool
by: Natasha Dilwali, et al.
Published: (2024-10-01)